Eris Lifesciences Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹791.55
- Today's High:
- ₹819.45
- Open Price:
- ₹812.05
- 52W Low:
- ₹550.9
- 52W High:
- ₹924
- Prev. Close:
- ₹815.75
- Volume:
- 12639
Company Statistics
- Market Cap.:
- ₹111.96 billion
- Book Value:
- 161.465
- Revenue TTM:
- ₹17.30 billion
- Operating Margin TTM:
- 25.6%
- Gross Profit TTM:
- ₹13.44 billion
- Profit Margin:
- 22.11%
- Return on Assets TTM:
- 8.83%
- Return on Equity TTM:
- 18.12%
Company Profile
Eris Lifesciences Limited had its IPO on under the ticker symbol ERIS.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Eris Lifesciences Limited has a staff strength of 0 employees.
Stock update
Shares of Eris Lifesciences Limited opened at ₹812.05 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹791.55 - ₹819.45, and closed at ₹807.85.
This is a -0.97% slip from the previous day's closing price.
A total volume of 12,639 shares were traded at the close of the day’s session.
In the last one week, shares of Eris Lifesciences Limited have increased by +0.3%.
Eris Lifesciences Limited's Key Ratios
Eris Lifesciences Limited has a market cap of ₹111.96 billion, indicating a price to book ratio of 4.5458 and a price to sales ratio of 6.241.
In the last 12-months Eris Lifesciences Limited’s revenue was ₹17.30 billion with a gross profit of ₹13.44 billion and an EBITDA of ₹5.75 billion. The EBITDA ratio measures Eris Lifesciences Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Eris Lifesciences Limited’s operating margin was 25.6% while its return on assets stood at 8.83% with a return of equity of 18.12%.
In Q2, Eris Lifesciences Limited’s quarterly earnings growth was a positive 0.3% while revenue growth was a positive 17.3%.
Eris Lifesciences Limited’s PE and PEG Ratio
- Forward PE
- 18.6916
- Trailing PE
- 29.8333
- PEG
Its diluted EPS in the last 12-months stands at ₹27.59 per share while it has a forward price to earnings multiple of 18.6916 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eris Lifesciences Limited’s profitability.
Eris Lifesciences Limited stock is trading at a EV to sales ratio of 6.3695 and a EV to EBITDA ratio of 18.0718. Its price to sales ratio in the trailing 12-months stood at 6.241.
Eris Lifesciences Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 26.17%.
Balance sheet and cash flow metrics
- Total Assets
- ₹36.67 billion
- Total Liabilities
- ₹4.43 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 26.17%
Eris Lifesciences Limited ended 2024 with ₹36.67 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹36.67 billion while shareholder equity stood at ₹21.96 billion.
Eris Lifesciences Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹4.43 billion in other current liabilities, 135990000.00 in common stock, ₹21.82 billion in retained earnings and ₹3.32 billion in goodwill. Its cash balance stood at ₹560.22 million and cash and short-term investments were ₹868.08 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹6.44 billion.
Eris Lifesciences Limited’s total current assets stands at ₹7.65 billion while long-term investments were ₹0 and short-term investments were ₹307.86 million. Its net receivables were ₹2.93 billion compared to accounts payable of ₹1.25 billion and inventory worth ₹1.31 billion.
In 2024, Eris Lifesciences Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Eris Lifesciences Limited paid ₹0.26 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹807.85
- 52-Week High
- ₹924
- 52-Week Low
- ₹550.9
- Analyst Target Price
- ₹
Eris Lifesciences Limited stock is currently trading at ₹807.85 per share. It touched a 52-week high of ₹924 and a 52-week low of ₹924. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹783.44 and 200-day moving average was ₹671.92 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 8104.9% of the company’s stock are held by insiders while 1493.7% are held by institutions.
Frequently Asked Questions About Eris Lifesciences Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, anti”diabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.